Hui Chen

Dr. Hui Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Biomaterials
Verified
Journal Article
Closed access
ZZZhiying Zeng
Zhiying Zeng
XHXiao He
Xiao He
CLChangying Li
Changying Li
SLShan Lin
Shan Lin
HCHui Chen
Hui Chen
XFXuli Feng
Xuli Feng

14 May 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
LYLan Yang
Lan Yang
XHXiao He
Xiao He
ZZZhiying Zeng
Zhiying Zeng
JTJiakun Tang
Jiakun Tang
DQDongmei Qi
Dongmei Qi
XFXuli Feng
Xuli Feng
Nucleus-targeted therapy holds great promise in cancer treatment; however, a lack of effective nucleus-specific delivery significantly limits its application potential. Here, we report a nucleus-targeted synergistic chemo-photodynamic therapy based on the self-assembly of chlorin e6 (Ce6) and doxorubicin (DOX) tuned by clickable dibenzocyclooctyne (DIBO) functionalized lysine (D-K) and subsequent reaction with crosslinkers. The assembled nanodrugs with high loading efficiency and long-term stability show enhanced cellular uptake and accumulation in the nucleus, resulting in greatly improved in vitro and in vivo chemo-photodynamic efficacy. Notably, D-K can promote the rapid self-assembly of Ce6 and DOX in aqueous solution, avoiding the introduction of organic solvents or tedious preparations. In addition, the introduction of the DIBO group can effectively expand the types of self-assembly material and enhance the self-assembly behaviour through a copper-free click reaction. Therefore, we present an effective nucleus-targeted combination drug delivery strategy, which has great potential in the treatment of many diseases.

24 May 2021 in Small
Verified
Journal Article
Closed access
PDF file
JTJiakun Tang
Jiakun Tang
YLYe Liu
Ye Liu
DQDongmei Qi
Dongmei Qi
LYLan Yang
Lan Yang
HCHui Chen
Hui Chen
XFXuli Feng
Xuli Feng

1 September 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
XHXiao He
Xiao He
LYLan Yang
Lan Yang
HSHang Su
Hang Su
SLShan Lin
Shan Lin
DQDongmei Qi
Dongmei Qi
XFXuli Feng
Xuli Feng

22 August 2022 in Chemical Science
Verified
Journal Article
Open access
PDF file
LYLan Yang
Lan Yang
HMHuijie Ma
Huijie Ma
SLShan Lin
Shan Lin
YZYupeng Zhu
Yupeng Zhu
HCHui Chen
Hui Chen
XFXuli Feng
Xuli Feng
Subcellular organelle targeted transport is of great significance for accurately delivering drugs to active sites for better pharmacological effects, but there are still a lot of challenges due to transport problems. In addition, the killing effect of one kind of drug on cells is limited. Therefore, it is necessary to develop a multifunctional nanoplatform that can co-deliver synergistic therapeutic agents. Here, we prepare a simple amphiphilic nanocarrier (LC) with rapid endosomal escape ability for nucleus-selective delivery of hydrophilic active protein deoxyribonuclease I (DNase I) and hydrophobic anticancer drug doxorubicin (DOX). LC has been applied to effectively encapsulate DNase I just by simply mixing their aqueous solutions together. In addition, DOX modified with adamantane groups via a redox-responsive linker is incorporated into the architecture of DNase I nanoformulations through host–guest interaction. This multi-component nanoplatform can quickly escape from the endolysosomes into the cytoplasm and make DNase I and DOX highly accumulate in the nucleus and consequently induce strong synergistic anticancer efficacy both in vitro and in vivo. This work illustrates a new platform for codelivery of proteins and drugs that target subcellular compartments for functions.

22 April 2020 in The Analyst
Verified
Journal Article
Closed access
PDF file
YTYaqin Tang
Yaqin Tang
XHXiao He
Xiao He
RYRui Yuan
Rui Yuan
XLXingming Liu
Xingming Liu
YZYi Zhao
Yi Zhao
XFXuli Feng
Xuli Feng
A multiplex miRNA detection scheme with simultaneous multiple signal output by single excitation has been reported.